Abstract
Patients presenting with Stage III or IV non-Hodgkin's malignant lymphoma were given chemotherapy; about 20% complete remission was obtained for both stages. The addition of radiotherapy increased the incidence to 70% in Stage III patients. The duration of first complete remission was longer for Stage III (25% of the patients are still in first remission at 7 years) than for Stage IV (0%). The survival was longer for nodular lymphosarcoma patients (25% are alive at 7 years for Stages III and IV) than for diffuse lymphosarcomata and reticulosarcomata (10%). Among the new drugs, VM 26 is able to produce a good frequency of remission in patients in relapse.
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Azirines / therapeutic use
-
Bleomycin / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Daunorubicin / therapeutic use
-
Etoposide / therapeutic use
-
Female
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / radiotherapy
-
Lymphoma, Large B-Cell, Diffuse / therapy*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / radiotherapy
-
Lymphoma, Non-Hodgkin / therapy*
-
Male
-
Prednisone / therapeutic use
-
Procarbazine / therapeutic use
-
Teniposide / therapeutic use
-
Triethylenemelamine / therapeutic use
-
Vinblastine / therapeutic use
-
Vincristine / therapeutic use
Substances
-
Antineoplastic Agents
-
Azirines
-
Bleomycin
-
Procarbazine
-
Vincristine
-
Vinblastine
-
Etoposide
-
Cyclophosphamide
-
Teniposide
-
Triethylenemelamine
-
Prednisone
-
Daunorubicin